Printer Friendly

SMITHKLINE BEECHAM AND APPLIED MICROBIOLOGY INC. ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP ORAL CARE PRODUCTS

 PHILADELPHIA, July 1 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) announced today that it has entered into an agreement with Applied Microbiology Inc. (NASDAQ Small Cap: AMBI) to jointly develop oral care and oral hygiene products utilizing AMBI's anti-microbial agent, Ambicin-N.
 The agreement requires SB to achieve certain development milestones to an agreed timetable and will provide SB with a worldwide exclusive license to use the resulting products for several years following introduction.
 John Budsworth, director and senior vice president, Research and Technical Operations, SB Consumer Brands said: "We have been working with and testing AMBI's technology and are excited about incorporating it into our product development. We feel that the new products will provide us with a competitive advantage and will result in an increased market share for our oral care business."
 David Guttmann, chairman of AMBI, added, "We are pleased that a leading international company such as SmithKline Beecham has recognized the value of our technology, and is planning to incorporate it in their oral care product development program. This program covers toothpastes and mouth rinses. We may eventually see it extended to oral sprays, dental floss, and denture products. These represent a $6.7 billion industry and even attaining a small percentage of the market would result in substantial profits for AMBI."
 AMBI is a New York-based biopharmaceutical company with operations in the United States and United Kingdom. It produces and markets safe and effective anti-microbial products under its trademarks Ambicin and
Nisaplin. Nisaplin, a naturally occurring anti-microbial food preservative preparation, is sold in more than 40 countries.
 SmithKline Beecham -- one of the world's leading healthcare companies - discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines, consumer healthcare products and clinical laboratory testing services.
 /delval/
 -0- 7/1/93
 /CONTACT: Sharyn Arnold, 215-751-5166, or Richard Williams (financial), 215-751-7002, both of SmithKline Beecham/
 (SBH AMBI)


CO: SmithKline Beecham; Applied Microbiology Inc. ST: Pennsylvania, New York IN: MTC SU: TNM

MP -- PH007 -- 7590 07/01/93 09:44 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1993
Words:331
Previous Article:PHILADELPHIA FEDERAL RESERVE BANK RELEASES LIVINGSTON SURVEY
Next Article:LUKENS AGREES TO SELL CORROSION PROTECTION COMPANIES
Topics:


Related Articles
U.S. BIOSCIENCE AND SMITHKLINE BEECHAM FORM ALLIANCE IN JAPAN, SOUTH KOREA AND TAIWAN
SMITHKLINE BEECHAM ACQUIRES CORSODYL FROM ICI
ADVANCED POLYMER SYSTEMS ANNOUNCES SALES, MARKETING AND PRODUCT DEVELOPMENT AGREEMENT WITH SMITHKLINE BEECHAM
ABBOTT AND SMITHKLINE BEECHAM SIGN MARKETING AND DISTRIBUTION AGREEMENT
SMITHKLINE BEECHAM'S CONSUMER HEALTH CARE DIVISION REACHES AGREEMENT WITH EPITOPE, INC. TO ENTER THE DIAGNOSTIC MARKET
TULANE UNIVERSITY AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
SMITHKLINE BEECHAM AND QMED ANNOUNCE STRATEGIC ALLIANCE
RIBI COMPLETES ADJUVANT LICENSE AGREEMENT FOR NEW SMITHKLINE BEECHAM PHARMA ALLERGY VACCINES IN DEVELOPMENT
Virus Research Institute Announces Rotavirus Vaccine Collaboration with SmithKline Beecham
MedImmune and SmithKline Beecham Form Worldwide Human Papillomavirus Vaccine Alliance

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters